Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Antineoplastic Agents. Found 201 abstracts

no pagination
Mehra R, Cohen RB, Harari PM. EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Current oncology reports. 2008 Mar;10(2):176-84.
Ozols RF. Gynecologic Oncology Group (GOG-USA) trials in ovarian cancer. Advances in experimental medicine and biology. 2008 Jan;622:131-43.
Parmar MK, Barthel FM, Sydes M, Langley R, Kaplan R, Eisenhauer E, Brady M, James N, Bookman MA, Swart AM, Qian W, Royston P. Speeding up the evaluation of new agents in cancer. Journal of the National Cancer Institute. 2008 Sep 03;100(17):1204-14.   PMCID: PMC2528020
Patel BB, He YA, Li XM, Frolov A, Vanderveer L, Slater C, Schilder RJ, von Mehren M, Godwin AK, Yeung AT. Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis. Cancer Genomics Proteomics. 2008 May;5(3-4):137-49.
Sanborn RE, Lally BE. Adjuvant therapy for non-small cell lung cancer with mediastinal nodal involvement. Thorac Surg Clin. 2008 Nov;18(4):423-35.
Serebriiskii I, Castello-Cros R, Lamb A, Golemis EA, Cukierman E. Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells. Matrix biology : journal of the International Society for Matrix Biology. 2008 Jul;27(6):573-85.   PMCID: PMC2603546
Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, Testa JR, Eisenberg B, von Mehren M, Godwin AK. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8387-92.   PMCID: PMC2448846
Zelenetz AD, Advani RH, Byrd JC, Czuczman MS, Damon LE, Duvic M, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Nademanee A, Olsen EA, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J, Yunus F, National Comprehensive Cancer N. Non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 2008 Apr;6(4):356-421.
Ariazi EA, Leitao A, Oprea TI, Chen B, Louis T, Bertucci AM, Sharma CG, Gill SD, Kim HR, Shupp HA, Pyle JR, Madrack A, Donato AL, Cheng D, Paige JR, Jordan VC. Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen. Mol Cancer Ther. 2007 Nov;6(11):2817-27.
Astsaturov I, Cohen RB, Harari P. EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets. 2007 Nov;7(7):650-65.
Crispen PL, Uzzo RG, Golovine K, Makhov P, Pollack A, Horwitz EM, Greenberg RE, Kolenko VM. Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention. The Prostate. 2007 May;67(6):582-90.
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global AT. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine. 2007 May 31;356(22):2271-81.
Litwin S, Wong YN, Hudes G. Early stopping designs based on progression-free survival at an early time point in the initial cohort. Statistics in medicine. 2007 Oct 30;26(24):4400-15.
Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol. 2006 Sep 10;24(26):4324-32.
Narra K, Borghaei H, Al-Saleem T, Hoglund M, Smith MR. Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: report of two cases and review of the literature. Leukemia Research. 2006 Jan;30(1):109-14.
Ozols RF, Bookman MA, du Bois A, Pfisterer J, Reuss A, Young RC. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. Gynecol Oncol. 2006 Oct;103(1):1-6.
Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9.
Tarn C, Godwin AK. The molecular pathogenesis of gastrointestinal stromal tumors . Clin Colorectal Cancer. 2006 Nov;6 Suppl 1:S7-17.
von Mehren M. Imatinib-refractory gastrointestinal stromal tumors: the clinical problem and therapeutic strategies. Current oncology reports. 2006 May;8(3):192-7.
Wetherbee SL. New weapons to snuff out kidney cancer. Nursing. 2006 Dec;36(12 Pt.1):58-63; quiz 64.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Antineoplastic Agents

Antineoplastic Agents drug therapy therapeutic use Female pharmacology metabolism Ovarian Neoplasms pathology Monoclonal Antibodies Tumor Cell Line genetics methods antagonists & inhibitors Neoplastic Gene Expression Regulation therapy Pyrimidines Piperazines Neoplasm Staging drug effects Disease-Free Survival Proto-Oncogene Proteins c-akt Middle Aged Gastrointestinal Stromal Tumors pa [Pathology] dt [Drug Therapy] Protein Kinase Inhibitors Combined Modality Therapy Antineoplastic Combined Chemotherapy Protocols Male Clinical Trials as Topic 0 (Antineoplastic Agents) Immunotherapy Cell Proliferation Proto-Oncogene Proteins c-kit United States Antitumor Drug Screening Assays Platelet-Derived Growth Factor alpha Receptor aa [Analogs & Derivatives] Neoplasm Metastasis Phase II Clinical Trials as Topic NF-kappa B Survival Analysis Prostatic Neoplasms Head and Neck Neoplasms Pyrroles Epidermal Growth Factor Receptor administration & dosage cytology Medical Oncology Randomized Controlled Trials as Topic Mice Signal Transduction Adult enzymology adverse effects Treatment Outcome Squamous Cell Carcinoma Time Factors Aged Kidney Neoplasms Renal Cell Carcinoma 80 and over Aged Prognosis Neoplasm Drug Resistance Phase III Clinical Trials as Topic Mutation Biological Tumor Markers Vitamin E Small Interfering RNA Drug Delivery Systems Cisplatin Fibroblasts Androstadienes Molecular Models Drug Approval Non-US Gov't Research Support Hydroxylation Lymphocytic Leukemia-Chronic IGF Type 1 Receptor Local Neoplasm Recurrence mortality Non-Small-Cell Lung Carcinoma ae [Adverse Effects] use Testicular Hormones Proportional Hazards Models ai [Antagonists & Inhibitors] Gynecologic Surgical Procedures 0 (cci 779) dosage Cell Adhesion Paclitaxel Enzyme-Linked Immunosorbent Assay EC 2-7-1-37 (Protein Kinases) Gene Silencing Glycoproteins 0 (Neoplasm Proteins) therapeutic adverse Verapamil 0 (rituximab) Sample Size statistics & numerical data Cell Survival Tissue Scaffolds ci [Chemically Induced] effects ad [Administration & Dosage] Cultured Tumor Cells Mass Spectrometry Predictive Value of Tests DNA Mutational Analysis 0 (Interferon-alpha) immunology de [Drug Effects] Androgen Receptors Metribolone Parenteral Infusions Platelet-Derived Growth Factor Receptors tu [Therapeutic Use] Postoperative Care Cell Cycle diagnosis 53123-88-9 (Sirolimus) Carboplatin Adjuvant Chemotherapy Nephrectomy Hematologic Diseases Genetic Transcription physiology Drug Dose-Response Relationship Neoplasm Proteins Interferon-alpha NIH 3T3 Cells Fluorescent Dyes Stem Cells United States Food and Drug Administration chemistry CHO Cells Anti-Mullerian Hormone Neoplasm Invasiveness standards Vascular Endothelial Growth Factor Receptors secondary Benzimidazoles Lymphatic Metastasis erbB-2 Receptor 0 (Protein Kinase Inhibitors) trends
Last updated on Wednesday, March 04, 2020